Daily GLP-1 tablets are widening access to obesity treatment and boosting industry expectations.Analysts now value the global market at up to $200bn by the early 2030s. Novo Nordisk launched the first oral version of Wegovy in the US.Early demand outpaced the original injection.Patients say pills feel easier to manage and avoid weekly shots.Lower storage needs and reduced prices also attract new users. Rival Eli Lilly is preparing its own tablet, orforglipron.More oral drugs from biotech firms are…